What Is Sermorelin? A GHRH (1-29) Research Guide

Sermorelin is a synthetic peptide made of the first 29 amino acids of human growth hormone-releasing hormone (GHRH), the hypothalamic signal that tells the pituitary gland to produce and release growth hormone. Truncation studies in the 1980s showed that this fragment, written GHRH (1-29), keeps essentially the full biological activity of the 44-amino-acid hormone at its receptor, and sermorelin is that fragment with a stabilizing amide group at its C-terminus.

Because it works upstream, at the pituitary, rather than supplying growth hormone itself, sermorelin became one of the most thoroughly characterized tools in growth-hormone-axis research. It was marketed for a time as a prescription product (Geref) for diagnostic testing and for growth hormone deficiency in children, withdrawn from the United States market in 2008 for commercial reasons, and is studied today as a laboratory research compound. This guide reviews what sermorelin is, how it acts at the GHRH receptor, why its half-life is measured in minutes, what the published research record actually shows, and how laboratories verify the material they work with.

What Is Sermorelin, Exactly?

Sermorelin is the biologically active core of a longer hormone. Natural GHRH is a 44-amino-acid peptide released by the hypothalamus. Systematic shortening experiments established that activity lives in the N-terminal portion of the molecule: residues 1 through 29 bind the GHRH receptor and trigger the full signaling response, while the remaining 15 residues contribute little to receptor activation.

• Also written as: GHRH (1-29)-NH2, GRF (1-29)-NH2, sermorelin acetate
• Length: 29 amino acids, C-terminally amidated
• Sequence: Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2
• Molecular weight: Approximately 3,357.9 g/mol
• CAS number: 86168-78-7
• Parent molecule: Human growth hormone-releasing hormone (44 amino acids)
• Class: GHRH receptor agonist (growth hormone secretagogue)

That minimal-fragment design is why sermorelin matters beyond its own literature. It was the reference point from which later, deliberately stabilized GHRH analogs were engineered, including modified GRF (1-29), CJC-1295, and tesamorelin, each of which changes part of sermorelin's blueprint to slow its breakdown. Researchers comparing those compounds usually start with sermorelin as the unmodified baseline.

Where Does Sermorelin Come From?

Sermorelin's history is unusually well documented for a research peptide. After the structure of GHRH was characterized in the early 1980s, Serono Laboratories developed the (1-29) fragment as the product Geref. The United States Food and Drug Administration approved it first, in 1990, as a diagnostic agent for testing pituitary growth hormone reserve, and again in 1997 for treating children with growth failure due to idiopathic growth hormone deficiency.

Serono discontinued Geref in 2008. The withdrawal was a commercial decision by the manufacturer and was not driven by safety or efficacy findings, a distinction that is often lost in secondary sources. Sermorelin was never approved for adult growth hormone deficiency or for any age-related indication, and it holds no current FDA approval. The clinical literature generated during its years as an approved product is precisely what keeps it relevant: few research peptides have published human pharmacokinetic and pharmacology data of comparable depth.

How Does Sermorelin Work at the GHRH Receptor?

Sermorelin binds the GHRH receptor, a Gs protein-coupled receptor expressed on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP, and that second-messenger signal does two things at once: it triggers the release of stored growth hormone into the circulation, and it supports new growth hormone synthesis inside the somatotroph.

Two properties follow from this upstream position. First, the growth hormone released after sermorelin stimulation comes in pulses shaped by the pituitary itself, resembling the gland's natural secretory pattern rather than a flat exogenous supply. Second, the normal feedback architecture of the axis stays in place: rising growth hormone and IGF-1 still signal back through somatostatin and related pathways, so the system retains its own braking mechanism in the models where this has been studied.

Published pharmacology also documents a clean selectivity profile. At exposures producing robust growth hormone peaks, studies report no measurable changes in prolactin, luteinizing hormone, follicle-stimulating hormone, insulin, cortisol, or blood glucose. For researchers, that selectivity is the practical point: sermorelin isolates the GHRH input to the axis, which makes it a precise probe for pituitary function and growth hormone dynamics.

Why Is Sermorelin's Half-Life So Short?

Sermorelin disappears from plasma in minutes. The most-cited pharmacokinetic work, by Wilton and colleagues in 1993, puts its plasma half-life at roughly 11 to 12 minutes, and some product-label data describe an even shorter window after intravenous administration. The reason is enzymatic: the bond after the second residue, alanine, is a preferred cutting site for dipeptidyl peptidase-4 (DPP-4), and unprotected GHRH fragments are dismantled quickly in circulation.

Citation: Wilton P, et al. Pharmacokinetic study of growth hormone-releasing hormone (1-29)-NH2 in children. Acta Paediatrica. 1993. [PubMed PMID: 8329825](https://pubmed.ncbi.nlm.nih.gov/8329825/)

That fragility became the design brief for the entire analog family that followed. Modified GRF (1-29) keeps sermorelin's 29-residue length but substitutes four amino acids to resist DPP-4 and other degradation routes. CJC-1295 adds further chemistry, including, in its DAC form, a group that binds albumin to extend circulation time; our CJC-1295 vs Ipamorelin comparison covers that branch of the family. Tesamorelin takes yet another route, keeping the full 44-residue sequence and protecting it with a trans-3-hexenoyl cap, as reviewed in our Tesamorelin research guide. Sermorelin, by contrast, is the unmodified fragment, which is exactly why it remains the comparison standard.

Sermorelin and Its Successors at a Glance

Compound	Sequence basis	Key modification	Reported plasma half-life
Sermorelin	GHRH (1-29), amidated	None — the native fragment	~11–12 minutes
Modified GRF (1-29) / CJC-1295 (no DAC)	GHRH (1-29)	Four stabilizing amino-acid substitutions	~30 minutes
Tesamorelin	Full-length GHRH (1-44)	Trans-3-hexenoyl cap at the N-terminus	Longer than sermorelin; studied on a daily schedule in trials

Read as a set, the three designs answer the same question three different ways: how to keep a GHRH signal present long enough to study. Sermorelin's short half-life is not a defect in that comparison. It is the property that makes it useful for provocation-style experiments, where a brief, defined pulse of receptor stimulation is the variable under study.

What Has the Published Research Found?

The strongest part of sermorelin's record is pediatric. In the multicenter trial run by the Geref International Study Group, children with growth hormone deficiency treated with daily GHRH (1-29) grew substantially faster than their pretreatment rate: height velocity rose to about 7.4 cm per year at six months and about 7.2 cm per year at twelve months, from a baseline near 4 cm per year, without excessive IGF-1 generation reported by the investigators.

Citation: Geref International Study Group. Multicenter trial of GHRH (1-29) in children with growth hormone deficiency. 1996. [PubMed PMID: 8772599](https://pubmed.ncbi.nlm.nih.gov/8772599/)

Earlier pediatric work by Ross and colleagues in 1987 pointed the same way, with first-year height velocity rising from roughly 4 cm per year to roughly 8 cm per year in the children studied. Adult data exist but are thinner: in healthy older men, published studies of subcutaneous GHRH (1-29) reported dose-related increases in 24-hour growth hormone and IGF-1 over short treatment periods, with no change in fasting glucose reported. These were small, short physiology studies, and the literature does not support extrapolating them into general claims about aging.

Read carefully, the record supports a narrow conclusion: sermorelin reliably stimulates the pituitary to release growth hormone in the settings where it has been tested, its pharmacology is well characterized, and its evidence base is concentrated in growth hormone deficiency diagnostics and pediatric growth research. Anything beyond that is extrapolation, and this guide does not make it.

How Is Sermorelin Used in Laboratory Research Today?

With no current drug approval, sermorelin's present-day role is as a research compound, and laboratories use it in several defined ways:

• GH-axis physiology models: probing how the hypothalamic-pituitary axis responds to a defined GHRH input in cell and animal systems.
• Pituitary function studies: the same provocation logic that underpinned its diagnostic era, applied in preclinical research settings.
• Structure-activity reference: the unmodified baseline against which stabilized analogs such as modified GRF (1-29) and CJC-1295 are compared.
• Analytical standard: a well-characterized peptide for calibrating identity and purity methods for the GHRH analog family.

In each role, the experimental variable is the compound's signaling behavior, so the identity and purity of the material are part of the experimental design rather than an afterthought, which leads directly to the verification question below.

How Do Researchers Verify Sermorelin Material?

Two analytical checks are standard for a peptide of this size. Mass spectrometry should confirm a molecular identity consistent with the 29-residue amidated sequence at approximately 3,357.9 g/mol, distinguishing intact sermorelin from truncated or deamidated variants. Reversed-phase HPLC is the standard purity method, quantifying the main peak against deletion sequences and other synthesis-related impurities that a short, heavily studied peptide can still carry.

Because a degradation product of sermorelin can be inactive at the receptor yet invisible to a nonspecific assay, researchers look for a batch-specific Certificate of Analysis documenting HPLC purity and mass spectrometry identity for the exact batch supplied. NUPEPS PEPTIDES publishes batch Certificates of Analysis for its research materials, available at nupeps.com/coas, and our guide to reading a peptide COA explains how to check one line by line. NUPEPS PEPTIDES tests every batch for purity, quantity, and sterility.

Sermorelin Research Material at NUPEPS PEPTIDES

NUPEPS PEPTIDES supplies sermorelin as a lyophilized research material, Sermorelin 10MG, for laboratory and in vitro research use only. Each batch is accompanied by its Certificate of Analysis, so the material can be matched to its analytical record before it enters an experiment. Sermorelin is supplied strictly as a research chemical; it is not a drug, and it is not for human or veterinary use.

Frequently Asked Questions

What is sermorelin made of?

Sermorelin is a synthetic copy of the first 29 amino acids of human growth hormone-releasing hormone, with an amide group at the C-terminus. That fragment is the shortest part of the natural 44-amino-acid hormone that retains full activity at the GHRH receptor, which is why it became the standard research form of the molecule.

Is sermorelin the same as growth hormone?

No. Growth hormone is a 191-amino-acid protein produced by the pituitary. Sermorelin is a much smaller signaling peptide that acts one step earlier: it binds the GHRH receptor on pituitary somatotrophs and prompts the gland to synthesize and release its own growth hormone in pulses.

Why did later analogs change sermorelin's sequence?

Because sermorelin is cut rapidly by enzymes such as DPP-4, giving it a plasma half-life of roughly 11 to 12 minutes. Modified GRF (1-29) substitutes four residues to resist that cutting, CJC-1295 adds further stabilizing chemistry, and tesamorelin protects the full-length sequence with a chemical cap. Each successor trades sermorelin's simplicity for longer exposure.

Is sermorelin an approved drug?

Not currently. It was FDA-approved as Geref for diagnostic testing in 1990 and for pediatric growth hormone deficiency in 1997, and the manufacturer discontinued it in 2008 for commercial reasons unrelated to safety or efficacy. Today it is sold only as a research chemical for laboratory use.

How can a researcher check sermorelin quality before an experiment?

Ask for the batch-specific Certificate of Analysis and check two things: mass spectrometry identity matching the expected molecular weight of about 3,357.9 g/mol, and HPLC purity of at least 99 percent for the batch actually supplied. A generic specification sheet that is not tied to the batch is not a substitute.

Conclusion

Sermorelin is the original GHRH research tool: the minimal active fragment of the natural hormone, selective for the pituitary GHRH receptor, and backed by an unusually complete published record for a research peptide, from pharmacokinetics to a multicenter pediatric trial. Its minutes-long half-life explains both its best research use, a brief and defined pulse of axis stimulation, and the entire family of stabilized analogs that were engineered after it.

For laboratories sourcing sermorelin today, the standard that matches its history is documentation: identity confirmed by mass spectrometry, purity of at least 99 percent by HPLC, and a Certificate of Analysis issued for the specific batch in hand. Material verified that way can be used with confidence in the experiments the compound was characterized for. This article is educational material about a research compound and is not medical advice.